Cytochrome P450 2C19 Polymorphism is Associated with Reduced Clopidogrel Response in Cerebrovascular Disease
Authors:
Open Access
- 1 January 2011
- journal article
- research article
- Published by Yonsei University College of Medicine in Yonsei Medical Journal
- Vol. 52 (5) , 734-738
Abstract
Lee JB, et al. Yonsei Med J. 2011 Sep;52(5):734-738. http://dx.doi.org/10.3349/ymj.2011.52.5.734Keywords
This publication has 21 references indexed in Scilit:
- Identification of the Human Cytochrome P450 Enzymes Involved in the Two Oxidative Steps in the Bioactivation of Clopidogrel to Its Pharmacologically Active MetaboliteDrug Metabolism and Disposition, 2010
- Relation of Genetic Polymorphisms in the Cytochrome P450 Gene With Clopidogrel Resistance After Drug-Eluting Stent Implantation in KoreansThe American Journal of Cardiology, 2009
- Cytochrome P-450 Polymorphisms and Response to ClopidogrelNew England Journal of Medicine, 2009
- Genetic Determinants of Response to Clopidogrel and Cardiovascular EventsNew England Journal of Medicine, 2009
- Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort studyThe Lancet, 2009
- Resistance to clopidogrel: A review of the evidenceJACC, 2005
- Variability in platelet responsiveness to clopidogrel among 544 individualsJACC, 2005
- Individual variations of platelet inhibition after loading doses of clopidogrelJournal of Internal Medicine, 2002
- ADP induces partial platelet aggregation without shape change and potentiates collagen-induced aggregation in the absence of Galphaq.2000
- Activation of G12/G13 Results in Shape Change and Rho/Rho-Kinase–mediated Myosin Light Chain Phosphorylation in Mouse PlateletsJournal of Cell Biology, 1999